In this article, the authors aimed to assess whether post-implant transcatheter aortic valve prosthesis multi-detector computed characteristics differ between patients with native tricuspid and bicuspid aortic valve stenosis, as well as the effect on valve performance and clinical outcomes.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transcatheter
January 23, 2025
January 23, 2025
This retrospective analysis examined trends and outcomes of aortic valve replacement in patients under the age of 65 with aortic stenosis from 2013 to 2021, focusing on transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR).
January 20, 2025
This video documents how to perform a second redo mitral valve replacement in an 82-year-old woman with a previous mitral valve repair and replacement.
January 2, 2025
Over the past year, CTSNet JANS editors have done an excellent job at gathering relevant and compelling news in cardiothoracic surgery, covering topics such as multiarterial versus single-arterial coronary surgery and transcatheter or surgical treatment of aortic valve stenosis.
December 12, 2024
In this study, the authors conducted an in-depth analysis of the health status of patients enrolled in the TRISCEND II pivotal trial (Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device) to help quantify the benefit of intervention for these patients.
December 12, 2024
In the TRISCEND II trial, a total of 400 patients with severe symptomatic tricuspid regurgitation were randomized in a 2:1 ratio to undergo either transcatheter tricuspid valve replacement with medical therapy (valve-replacement group) or medical therapy alone (control group).
December 5, 2024
Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis.
November 26, 2024
Neurohormonal modulation and afterload reduction are essential for treating heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), therapy with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT).
November 26, 2024
This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.
November 26, 2024
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes.